Logo
Logo

About Abiraterone Acetate API

Product
  • Therapeutic CategoryAnti-Cancer/ Oncology

  • API Technology

    Steroids

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF, EUDMF, Korea DMF, Russia DMF

Mechanism of Action

Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism.

Indication

ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with

  • Metastatic castration-resistant prostate cancer (CRPC).
  • Metastatic high-risk castration-sensitive prostate cancer (CSPC)

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Description not provided

FAQs

What drug class is ABIRATERONE ACETATE API?
  • It belongs to Anti-neoplastic drug class

What is ABIRATERONE ACETATE API used to treat?
  • It is a oncology product used to treat Metastatic castration-resistant prostate cancer (CRPC). Metastatic high-risk castration-sensitive prostate cancer (CSPC)

What are the dosage strengths available for ABIRATERONE ACETATE API ?
  • Abiraterone is available in 250 mg and 500 mg dosage forms

What are offerings of Dr. Reddy's for ABIRATERONE ACETATE API?
  • We offer polymorph Form-A for Abiraterone API

What is the process available for ordering ABIRATERONE ACETATE API?

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.